Agilent Technologies stock ticks higher after strong Q3 earnings and raised 2026 outlook
Published on 08/28/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Agilent Technologies (US00846U1016) stock is holding close to recent highs after the company reported solid third-quarter fiscal 2026 results and raised its earnings guidance for the full year, with shares last closing at $157.69 on August 27, 2026.
Per the latest results for the quarter ended July 31, 2026, Agilent delivered revenue of $1.88 billion and non-GAAP earnings per share of $1.62, both ahead of the consensus view and supported by stronger margins in its core businesses. The updated outlook for fiscal 2026 now calls for higher adjusted EPS, underscoring management's confidence in demand across life sciences, diagnostics and applied markets.
For investors, the combination of accelerating top-line growth and clear margin expansion has shifted attention toward how much earnings power Agilent can sustain into 2027.
Q3 2026 earnings beat and margin expansion
In its fiscal third quarter ended July 31, 2026, Agilent reported total revenue of $1.88 billion, an 8.1 percent increase versus the same quarter of 2025 on a reported basis and 7.3 percent growth on a core basis as detailed in the company’s financial tables. The Agilent earnings release highlights that this revenue growth was broad-based across key segments and geographies.
On profitability, Agilent posted a GAAP operating margin of 23.6 percent for Q3 2026, expanding by 290 basis points year over year and 190 basis points sequentially, according to the same financial disclosure. The company presentation also shows a non-GAAP operating margin of 28.3 percent, which widened by 320 basis points versus Q3 2025 and by 190 basis points compared with the previous quarter, helped in part by a one-time tariff refund benefit.
GAAP net income for the quarter reached $362 million, translating into GAAP EPS of $1.28, an 8 percent increase over the prior-year quarter as outlined in the release. Non-GAAP net income came in at $459 million, with non-GAAP EPS of $1.62, up 18 percent from Q3 2025 and including a $0.06 per-share contribution from the tariff refund. The Q3 2026 tables confirm that the earnings beat was driven by both revenue growth and cost discipline.
Compared with the consensus EPS estimate of $1.49 described in recent market data coverage, Agilent exceeded expectations by $0.13 per share in Q3 2026. One recent analyst summary notes that revenue also topped typical forecasts of $1.84 billion, giving the quarter a clean beat on both the top and bottom lines.
Higher 2026 outlook and analyst view
Following the Q3 release dated August 26, 2026, Agilent increased its full-year fiscal 2026 guidance, signaling confidence that recent momentum can carry into the final quarter of the year. A recent summary of management commentary indicates that the company now projects adjusted EPS of $6.18 to $6.21 for fiscal 2026, compared with an earlier consensus expectation of $6.06.
For the upcoming fourth quarter of fiscal 2026, Agilent has provided guidance for adjusted EPS in a range of $1.71 to $1.74, according to the same overview. Market data following the Q3 report reiterates that management expects demand trends to remain healthy across its major end markets, with life sciences and diagnostics singled out as key growth drivers.
Recent coverage of the earnings call emphasizes that organic revenue growth of around 7 percent, combined with the more efficient cost structure, has allowed Agilent to translate top-line gains into faster-growing earnings per share. A video interview with the Agilent chief executive underscores that the company sees continued opportunity in biopharma and clinical diagnostics, areas where recurring revenue and service contracts support visibility.
Analyst sentiment toward the stock remains constructive. A recent analyst rating compilation shows that Agilent carries an average recommendation of Moderate Buy and a consensus price target of $170.33. That implies upside of roughly 8 percent from the recent $157.69 close, suggesting that the market has not yet fully priced in the improved margin and guidance picture.
Stock performance and valuation context
Agilent shares closed at $157.69 on the New York Stock Exchange on August 27, 2026, after gaining 1.68 percent during the session in what was described as a favorable trading day for the broader market. A same-day trading recap notes that this marked the third consecutive advance for the stock.
The same report shows that Agilent's $157.69 close compares with a recent average analyst price objective in the low $170s, and that the share price has delivered a year-to-date gain of 15.04 percent versus 12.53 percent for the S&P 500 Index as of August 28, 2026. A performance summary page adds that Agilent's one-year total return stands at 25.52 percent, outpacing the S&P 500's 18.47 percent over the same period.
From a shorter-term perspective, recent analysis highlights that Agilent has generated a 30-day share price return of 12.20 percent and a one-year total shareholder return of 27.21 percent through late August 2026. A detailed overview of investor interest notes that after this move the stock trades roughly 10 percent below the average analyst price target, a level that leaves room for further gains if the company continues to execute on its guidance.
For valuation-focused investors, that gap between the current share price and the consensus target, together with the upgraded EPS outlook, frames Agilent as a quality growth name trading at a premium to the market but not at extremes compared with its own recent history.
Institutional interest and ownership trends
Alongside the earnings beat and guidance hike, institutional investors have been adjusting their positions in Agilent during the latest quarter. Several recent regulatory filings summarize new or increased stakes by asset managers and pension funds that collectively underscore the stock's appeal as a core holding in life sciences tools and diagnostics.
One filing reviewed on August 28, 2026 reports that an institutional investor initiated a position in Agilent shares, citing the company's strong balance sheet, mid-single-digit to high-single-digit organic growth, and margin expansion as key attractions. An institutional-ownership overview also mentions that the latest quarter's return on equity reached 24.84 percent, with a net margin of 19.53 percent, underlining the business's profitability profile.
These figures complement the reported 8.1 percent year-over-year revenue growth for Q3 2026 and the 18 percent non-GAAP EPS increase versus the same period in 2025. For long-term holders, sustained returns on equity in the mid-20s, combined with expanding operating margins, often serve as a signal that the company is successfully leveraging its installed base and recurring revenue streams.
Recent commentary has also pointed out that Agilent's full-year guidance implies adjusted EPS growth in the high single digits to low double digits versus the prior year, depending on where results land within the $6.18 to $6.21 range. When set against the company's track record of beating consensus by $0.13 per share in Q3 2026, some investors see the outlook as prudent rather than aggressive.
Life sciences and diagnostics solutions
Agilent is best known for its portfolio of analytical instruments, consumables and software that laboratories use to analyze chemicals, biological samples and complex materials. Its life sciences and applied markets segment includes chromatography systems, mass spectrometry instruments and related workflows that are critical for pharmaceutical development, environmental testing and food safety analysis.
In the diagnostics and genomics area, Agilent provides reagents, instruments and automation platforms used in clinical laboratories and research settings to detect diseases, profile genetic material and support precision medicine initiatives. Demand in this segment has benefited from long-term trends such as aging populations, increased cancer screening and the growth of molecular testing.
Management commentary around the Q3 2026 results stressed that biopharma customers are continuing to invest in tools needed for biologics and cell and gene therapies, while academic and government labs are gradually normalizing spending. Together, these factors help support mid-to-high single-digit core revenue growth, which in turn feeds through to higher earnings when combined with the margin improvements reported in the latest quarter.
Agilent stock and recent trading levels
Agilent trades on the New York Stock Exchange under the ticker A, with its stock price reflecting both the company’s recent operational performance and broader market sentiment toward life sciences tools providers. The most recent completed close of $157.69 on August 27, 2026, places the stock within reach of the average analyst price target in the low $170s discussed in recent research roundups.
Market data compiled as of the afternoon of August 28, 2026 show that Agilent's trailing total return year to date stands at 15.04 percent, while its one-year total return of 25.52 percent continues to beat the S&P 500 benchmark. The latest performance table reinforces the narrative that the stock has offered both defensive qualities and growth exposure for diversified portfolios.
For investors tracking the name, the key questions now revolve around whether Agilent can sustain high-teens non-GAAP EPS growth beyond fiscal 2026, and how the market will value that earnings trajectory relative to peers in instrumentation and diagnostics. With guidance now pointed higher and recent quarters showing consistent execution, the stock continues to trade as a high-quality compounder within its sector.
Read more
More on Agilent Technologies stock
Key platforms and solutions
Beyond the headline financials, Agilent's investment case is closely tied to its strength in chromatography, mass spectrometry and genomics. The company offers integrated systems that pair high-performance instruments with software and consumables, creating sticky customer relationships and recurring revenue streams.
Flagship platforms in liquid chromatography and gas chromatography support a wide range of applications, from small-molecule drug development to food and environmental testing. These instruments are designed to deliver high throughput and precision, which can be critical when labs are processing thousands of samples and must meet strict regulatory standards.
Agilent's mass spectrometry lineup, including high-resolution accurate mass systems, is used for complex analyses such as metabolomics, proteomics and trace-level impurity detection. In diagnostics, the company supplies reagents and companion diagnostics tests that are used in cancer and genetic testing, often in partnership with pharmaceutical companies developing targeted therapies.
By continuing to invest in automation, digital workflows and cloud-connected software, Agilent aims to make laboratory operations more efficient and to deepen integration into customer processes. These initiatives support the margin expansion that showed up in the Q3 2026 operating results and are likely to remain a focus as management seeks to sustain high-return growth.
Agilent stock at the latest close
Agilent Technologies stock last closed at $157.69 on the New York Stock Exchange on August 27, 2026, with that price reflecting a year-to-date gain of 15.04 percent and a one-year total return of 25.52 percent versus 12.53 percent and 18.47 percent respectively for the S&P 500. For investors evaluating the shares after the Q3 2026 earnings beat and guidance increase, the stock now trades modestly below the consensus analyst price target of $170.33, leaving some room for potential upside if the company delivers on its higher outlook.
Fact box
Company: Agilent Technologies Inc.
ISIN: US00846U1016
Ticker: A
Exchange: NYSE
Price (as of August 27, 2026, 4:00 p.m. ET): $157.69 USD
Market cap: $46.2 billion (as of August 28, 2026)
Sector / Industry: Life Sciences Tools and Services
Index membership: S&P 500
